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ANDERSEN CASCADE IMPACTOR STUDY
8 stage non-viable Anderson cascade impactor (Westech Scientific Instruments Marietta, GA) was used to determine the aerodynamic particle size
distribution of the formulation.

Each of the plates of the impactor was coated with
Tween 80 to prevent bouncing of particles during
nebulization and were thereafter weighed. A filter
paper was placed on the last collector stage
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Parameter

Value

Particle size

386 ± 25 nm

Polydispersity
Index

0.32 ± 0.03

Zeta Potential

1.08 ± 0.95 mV

% Entrapment

58.32 ± 2.1 %

TABLE 1: Parameter for amikacin
inhalational NL before extrusion
process (mean ± SD, n=3)

Day 7 Day 21
Days

The particle size data signifies that the
formulation maintained its particle size
range for a period of 21 days indicating
that Amikacin loaded NL’s were stable.
Parameter
Particle size
Polydispersity Index

Value
215.26 ± 0.49 nm
0.43 ± 0.02

Zeta Potential

0.08 ± 0.015 mV

% Entrapment

63.45 ± 1.1 %

TABLE 2: Parameter for amikacin
inhalational NL after extrusion process
(mean ± SD, n=3)

Day 7
Days

Day 21

ACI components

The polydispersity index data signifies
that the formulation maintained its
particle size range for a period of 21 days
indicating no agglomeration meaning that
Amikacin loaded NL’s were stable.
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Graph 4: % Deposition in ACI components
Graph 5: Two point Linear Interpolation
The MMAD and GSD for the Amikacin were found to be 4.13±0.134 um and 1.82±0.064 respectively.

CONCLUSION(S)
The Amikacin loaded nanolipsomes were successfully formulated with characteristics similar to
Arikayce® with particle size range of less than 300nm.
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FUTURE WORK
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The future optimization of Ethanol injection method (formulation and process parameters), in vitro,
and preclinical in vivo testing are needed to test the developed Amk-NLs.
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• Using a syringe pump, the ethanolic lipid solution was injected into 0.9%w/v
Sodium Chloride solution containing drug at 50°C at a flow rate of
0.15mL/min, while continuously stirring at 600 rpm.
• Stir the solution continuously at 600 rpm for 30 min after the injection is
completed, maintaining the temperature.
• Using an avanti mini extruder, the formulation was passed through a 0.1µm
membrane to achieve particle size of less than 250 nm.
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Preparation
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• Prepare 1.3mL 90%V/V ethanolic solution. Add 17.29mg DPPC and 8.65mg
Cholesterol.
• Stir well for the lipids to completely dissolve in the ethanolic solution giving
clear solution at 50°C.
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RESULTS

Plate 2

Graph 1: Particle Size variation for 21 days

• Prepare 20mL 0.9%w/v solution of Sodium Chloride and add 50 mg Amikacin
to it to form 1.10mg/ml drug concentration of final formulation. Let it
dissolve completely at 50°C.

After nebulization, the impactor was
dissembled and all the plates were
again weighed. The mass median
aerodynamic diameter (MMAD),
geometric standard deviation (GSD)
of the formulation were calculated
according to the formulas given in
USP chapter <601>.

The % fine particle fraction after the experiment was found to be 42.01± 6.901.

Figure 3: Andersen Cascade Impactor Study.

Graph 2: Polydispersity Index variation for 21 days

FORMULATION DEVELOPMENT

A compressor nebulizer, Sami the
Seal (Philips Respironics, NJ) was
operated at a flow rate of
28.3+0.5 L/min as recommended
by United States
Pharmacopeia(USP) and the
formulation was nebulized for 10
minutes.

Plate 1

Mycobaterium avium complex (MAC) lung disease is a serious condition, that in some
cases can cause severe, even permanent damage to the lungs1. Amikacin is a
polycationic, semisynthetic, bactericidal aminoglyocoside. The entry of the moiety is
mediated by binding of the antibacterial moiety to the negatively charged components
of the bacterial cell wall. The primary mechanism of action involves the disruption and
inhibition of protein synthesis in the target bacteria by binding to the 30S ribosomomal
subunit. Arikayce® approved by FDA in 2018 and generic of Arikayce® is not available at
the moment. Due to the complex NLs dosage form, the development of generics takes a
longer time compared to the conventional dosage form. The aim is to develop and
characterize the Amikacin (Amk) loaded extended release nanoliposomes (NLs) by
ethanol injection method.
Central Hypothesis:- Inhaled Amk-NLs will produce a robust and consistent quality
inhaled Amk-NLs for the treatment of MAC lung disease.
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Graph 3: Zeta Potential variation for 21 days
The zeta potential data signifies that the formulation
maintained its charge range for a period of 21 days
indicating that Amikacin loaded NL’s were stable.
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